Journal of the American Academy of Dermatology
Volume 62, Issue 2 , Pages 205-217 , February 2010

Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial

Presented at the 2008 Conference of the American Academy of Dermatology, San Antonio, TX, March 2008; the 2009 Conference of the American Academy of Dermatology, San Francisco, CA, March 2009; and the 2007 Annual Conference of the British Association of Dermatologists, Birmingham, UK, June 2007.

  • Annika Grant, RN

      Affiliations

    • Florida Academic Dermatology Centers, Miami, Florida
    • ,
  • Tayler Gonzalez, PharmD

      Affiliations

    • Centocor Inc, Horsham, Pennsylvania
    • ,
  • Michael O. Montgomery, MD

      Affiliations

    • Centocor Inc, Horsham, Pennsylvania
    • ,
  • Vanessa Cardenas

      Affiliations

    • Florida Academic Dermatology Centers, Miami, Florida
    • ,
  • Francisco A. Kerdel, MBBS

      Affiliations

    • Florida Academic Dermatology Centers, Miami, Florida
    • Corresponding Author InformationReprint requests: Francisco A. Kerdel, MBBS, Florida Academic Dermatology Centers, 1400 NW 12 St, Suite 4, Miami FL 33136.

,Accepted 10 June 2009.

References 

  1. Poli F, Jemec GBE, Revuz J. Clinical presentation. In:  Jemec GBE,  Revuz J,  Leyden JJ editor. Hidradenitis suppurativa. Heidelberg (Germany): Springer-Verlag; 2006;p. 11–24
  2. In:  Jemec GBE,  Revuz J,  Leyden JJ editor. Hidradenitis suppurativa. Heidelberg (Germany): Springer-Verlag; 2006;
  3. Krbec AC. Current understanding and management of hidradenitis suppurativa. J Am Acad Nurse Pract. 2007;19:228–234
  4. Gao M, Wang PG, Cui Y, Yang S, Zhang YH, Lin D, et al. Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1-1q25.3. J Invest Dermatol. 2006;126:1302–1306
  5. Von Der Werth JM, Williams HC, Raeburn JA. The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol. 2000;142:947–953
  6. Fitzsimmons JS, Guilbert PR, Fitzsimmons EM. Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol. 1985;113:1–8
  7. Jemec GB, Thomsen BM, Hansen U. The homogeneity of hidradenitis suppurativa lesions: a histological study of intra-individual variation. APMIS. 1997;105:378–383
  8. Jansen I, Altmeyer P, Piewig G. Acne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol. 2001;15:532–540
  9. Oprica C, Nord CE. Bacteriology of hidradenitis suppurativa. In:  Jemec GBE,  Revuz J,  Leyden JJ editor. Hidradenitis suppurativa. Heidelberg (Germany): Springer-Verlag; 2006;p. 86–94
  10. Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa: a clinicopathological study of early lesions. Br J Dermatol. 1996;135:721–725
  11. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56:621–623
  12. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144:809–813
  13. Harrison BJ, Mudge M, Hughes LE. The prevalence of hidradenitis suppurativa in South Wales. In:  Marks R,  Plewig G editor. Acne and related disorders. London: Martin Dunitz Ltd; 1988;pp. 365-66
  14. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–194
  15. Jemec GB. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother. 2004;5:1767–1770
  16. Slade DE, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg. 2003;56:451–461
  17. Kagan RJ, Yakuboff KP, Warner P, Warden GD. Surgical treatment of hidradenitis suppurativa: a 10-year experience. Surgery. 2005;138:734–741
  18. Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg. 2000;26:638–643
  19. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs. 2002;16:111–148
  20. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534–542
  21. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis. 2001;7:323–326
  22. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol. 2002;97:2155–2156
  23. Gupta AK, Skinner AR. A review of the use of infliximab to manage cutaneous dermatoses. J Cutan Med Surg. 2004;8:77–89
  24. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876–885
  25. Bhalla R, Sequeira W. Arthritis associated with hidradenitis suppurativa. Ann Rheum Dis. 1994;53:64–66
  26. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat. 2005;16:58–61
  27. Roussomoustakaki M, Dimoulios P, Chatzicostas C, Kritikos HD, Romanos J, Panayiotides JG, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol. 2003;38:1000–1004
  28. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158:370–374
  29. Kristensen M, Chu CQ, Eedy DJ, Feldmann M, Brennan FM, Breathnach SM. Localization of tumor necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol. 1993;94:354–362
  30. Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5:729–735
  31. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139:1540–1542
  32. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149:1046–1049
  33. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2003;49(Suppl):S275–S276
  34. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624–628
  35. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol. 2007;46:1287–1291
  36. Drucker AM, Winkelman WJ, Walsh S, Shear NH. Long term experience with infliximab in hidradenitis suppurativa and pyroderma gangrenosum: a case series of 9 patients. Presented orally at: Canadian Dermatology Association 83rd Annual Conference, June 2008, Montreal.
  37. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet. 2005;366:1367–1374
  38. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:e1–e15
  39. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol. 2004;31:1538–1545
  40. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216
  41. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, Mouktaroudi M, Spyridaki E, Baziaka F, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol. 2007;156:51–56
  42. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17:45–56
  43. Fernandez-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology. 2007;215:41–44
  44. Revuz J. Modifications to the Sartorius score and instructions for evaluating the severity of suppurative hidradenitis. Ann Dermatol Venereol. 2007;134:173–174
  45. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211–213
  46. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158:567–572
  47. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971–974
  48. Mortimer PS, Dawber RP, Gales MA, Moore RA. Mediation of hidradenitis suppurativa by androgens. Br Med J (Clin Res Ed). 1986;292:245–248
  49. Mortimer PS, Lunniss PJ. Hidradenitis suppurativa. J R Soc Med. 2000;93:420–422
  50. Revuz J. The role of surgery in the treatment of hidradenitis suppurativa. Ann Dermatol Venereol. 2008;135:349–350
  51. Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med. 1995;88:289-90
  52. Jemec GB. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol. 2002;27:528–529
  53. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154:726–729
  54. Moul DK, Korman NJ. The cutting edge: severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 2006;142:1110–1112
  55. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359:1541–1549
  56. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601–608

 Supported by Centocor Inc.

 Disclosure: Dr Kerdel, Ms Grant, and Ms Cardenas have received research support from Centocor Inc. Drs Gonzalez and Montgomery are employees of Centocor Inc.

PII: S0190-9622(09)00782-8

doi: 10.1016/j.jaad.2009.06.050

Journal of the American Academy of Dermatology
Volume 62, Issue 2 , Pages 205-217 , February 2010

Article Tools

* Image Usage & Resolution